Article

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

2022-01-05

Abstract excerpt

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Two FDA approved anti-fibrotic drugs, nintedanib and pirfenidone, slow the rate of decline in lung function, but responses are variable and side effects are common. Using an in-silico data-driven approach, we identified a robust connection between the transcriptomic perturbations in IPF disease and those induced by saracatini...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ed11662a-cfd9-5c24-91e6-9cda7a8a423b
DOI: 10.1101/2022.01.04.474955

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary FibrosisDOI 10.1101/2022.01.04.474955Read

Profibrotic priming of airway cell types and drug responses in early-stage idiopathic pulmonary fibrosisSemantic proximity Read

Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosisSemantic proximity Read

Airway Basal Cells show a dedifferentiated KRT17 high Phenotype and promote Fibrosis in Idiopathic Pulmonary FibrosisSemantic proximity Read

Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis.Semantic proximity Read

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).Semantic proximity Read

Fibrotic human lung extracellular matrix as a disease-specific substrate for 3D in-vitro models of pulmonary fibrosisSemantic proximity Read

Expression profiles of nintedanib-targeting molecules in progressive fibrotic interstitial lung diseases (non-IPF-PF) and IPFSemantic proximity Read

Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesisSemantic proximity Read

Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosisSemantic proximity Read

Tankyrase inhibition demonstrates anti-fibrotic effects in preclinical pulmonary fibrosis modelsSemantic proximity Read

Transcriptional regulatory model of fibrosis progression in the human lungSemantic proximity Read

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in <i>In Vitro, In Vivo</i> and <i>Ex Vivo</i> Models of Pulmonary Fibrosis

Abstract excerpt

Topics

Identifiers and source

Related research